StockMarketWire.com - Investment group Mercia Technologies said it had made an additional £2.0m direct investment in pain and central nervous system product developer Medherant.

The investment was made as part of a £2.4m syndicated investment round.

Medherant was a clinical-stage company developing products using a unique transdermal delivery technology.


At 8:37am: [LON:MERC] Mercia Technologies Plc share price was 0p at 35p



Story provided by StockMarketWire.com